Drug Profile
Research programme: membrane protein inhibitor/antibacterial combinations - Rempex Pharmaceuticals
Alternative Names: MP-01,028Latest Information Update: 17 Jan 2020
Price :
$50
*
At a glance
- Originator Mpex Pharmaceuticals
- Developer The Medicines Company
- Class
- Mechanism of Action Cell wall inhibitors; Membrane protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 06 Jan 2020 The Medicines Company has been acquired by Novartis
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (Parenteral)
- 16 Dec 2013 This programme is still active